INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 346 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $308,040 | -34.1% | 10,103 | -31.6% | 0.22% | -38.2% |
| Q3 2023 | $467,249 | -24.1% | 14,777 | -2.1% | 0.36% | -11.1% |
| Q2 2023 | $615,411 | +18.8% | 15,091 | +8.5% | 0.40% | +11.3% |
| Q1 2023 | $518,202 | -3.3% | 13,904 | -9.5% | 0.36% | -18.4% |
| Q4 2022 | $536,000 | -34.2% | 15,371 | +5.6% | 0.44% | -35.5% |
| Q3 2022 | $815,000 | -80.9% | 14,558 | -82.4% | 0.69% | -29.7% |
| Q2 2022 | $4,270,000 | +446.7% | 82,499 | +667.4% | 0.98% | +86.1% |
| Q1 2022 | $781,000 | -27.7% | 10,751 | +17.7% | 0.53% | -27.7% |
| Q4 2021 | $1,080,000 | -9.4% | 9,134 | +2.8% | 0.73% | -11.4% |
| Q3 2021 | $1,192,000 | -20.5% | 8,886 | -4.0% | 0.82% | -19.3% |
| Q2 2021 | $1,499,000 | +86.9% | 9,256 | -7.4% | 1.02% | +28.6% |
| Q1 2021 | $802,000 | +210.9% | 9,994 | +110.9% | 0.79% | +154.2% |
| Q4 2020 | $258,000 | – | 4,739 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |